Breaking News Instant updates and real-time market news.

TEVA

Teva

$24.82

0.17 (0.69%)

16:44
09/20/18
09/20
16:44
09/20/18
16:44

Teva assumed with a Perform at Oppenheimer

Oppenheimer analyst Esther Rajavelu assumed Teva with a Perform rating, saying she is "cautiously optimistic" that the company is setting up to return to earnings growth and value creation in spite of continued revenue headwinds. The analyst adds that she is "fairly confident" that Teva can reduce its leverage with its existing cash as well as cash from from operations, but prefers a neutral stance until there is more evidence of a turnaround execution from the company's new management.

  • 20

    Sep

TEVA Teva
$24.82

0.17 (0.69%)

09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
09/17/18
09/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Sell at BTIG with analyst Timothy Chiang citing the positive impact of the FDA approval for Ajovy in the prevention of episodic and chronic migraines. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Stephens with analyst Vincent Caintic saying the company is successfully monetizing its card network by increasing merchant engagement to drive higher billed business volumes. 3. Lululemon (LULU) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. 4. Broadcom (AVGO) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying "so many positive takeaways from earnings" has forced him to take a more constructive stance on the shares. 5. MasterCard (MA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst James Schneider saying he continues to see upside to consensus estimates over the next 12 months driven by core consumer volume and exposure to Europe and other growth markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
WELS
09/17/18
NO CHANGE
Target $23
WELS
Market Perform
Migraine drug approval an 'important win' for Teva, says Wells Fargo
Wells Fargo analyst David Maris called news that the FDA has Teva's anti-CGRP treatment for the prevention of migraine an "important win" for the company given its lack of other near-term pipeline assets and continuing troubles in generics. Maris, who said not all investors thought Teva would get the approval given there was a previous setback, estimates 2018 North America sales of Ajovy of $10M and 2019 North America sales of $116M. He maintains a Market Perform rating and $23 price target on Teva shares.
09/17/18
BTIG
09/17/18
UPGRADE
BTIG
Neutral
Teva upgraded to Neutral from Sell at BTIG
BTIG analyst Timothy Chiang upgraded Teva to Neutral from Sell, citing the positive impact of the FDA approval for Ajovy in the prevention of episodic and chronic migraines. The analyst believes that the drug has the potential to become a "blockbuster product by 2022 with estimated sales of about $1B". Chiang further notes that the approval comes at a "critical" point for the new CEO Schultz as he leads a turnaround of the company, adding that the product label and a potential differentiation relative to other CGRP-antagonists will be key for Ajovy. The analyst models Ajovy sales reaching $500M in 2020.

TODAY'S FREE FLY STORIES

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGLS

Tecnoglass

$9.72

(0.00%)

16:35
10/19/18
10/19
16:35
10/19/18
16:35
Syndicate
Breaking Syndicate news story on Tecnoglass »

Tecnoglass files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/19/18
10/19
16:30
10/19/18
16:30
Options
Preliminary option volume of 24.7M today »

Preliminary option volume…

OXM

Oxford Industries

$81.36

-1.68 (-2.02%)

16:28
10/19/18
10/19
16:28
10/19/18
16:28
Conference/Events
Oxford Industries management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HELE

Helen of Troy

$120.52

0.31 (0.26%)

16:26
10/19/18
10/19
16:26
10/19/18
16:26
Conference/Events
Helen of Troy management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CGA

China Green

$0.74

0.0584 (8.57%)

16:21
10/19/18
10/19
16:21
10/19/18
16:21
Hot Stocks
China Green receives NYSE notice regarding late Form 10-K filing »

China Green Agriculture…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Options
Closing CBOE SPX and VIX Index summary for October 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Conference/Events
Morgan Stanley energy analyst to hold an analyst/industry conference call »

Refining & Canadian…

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Hot Stocks
Bristol-Myers updates on use of Opdivo and Yervoy in first-line lung cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNGO

Bionano Genomics

$6.98

0.08 (1.16%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Hot Stocks
Bionano Genomics and GrandOmics partner to offer genetic test for FSHD in China »

Bionano Genomics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.